EUVIMEDEUVIMED entdecken
Open Access

A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer

Neeta Pandit-Taskar, Joseph A O'Donoghue, Dushen Chetty, Steven Max, Danielle Wanik, Ohad Ilovich, Michael Russell, Tenzin Nyima, Chaitanya R Divgi, Margaret Yu, Michael J Morris

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.124.267416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Neeta Pandit-Taskar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantNeoplasm MetastasisHumansMaleTissue DistributionAgedMiddle AgedAntibodies, MonoclonalTissue KallikreinsIndium RadioisotopesIsotope LabelingHeterocyclic Compounds, 1-RingRadiopharmaceuticals

Stichwörter der Autor:innen

KLK2h11B6hK2mCRPC

Substanzen

Antibodies, MonoclonalTissue KallikreinsIndium RadioisotopesHeterocyclic Compounds, 1-RingRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiology, Weill Cornell Medical Center, New York, New York.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Janssen Research & Development, LLC, Spring House, Pennsylvania.
  • Invicro, LLC, Boston, Massachusetts.
  • Memorial Sloan Kettering Cancer Center, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

Pandit-Taskar, N., O'Donoghue, J. A., Chetty, D., Max, S., Wanik, D., Ilovich, O., Russell, M., Nyima, T., Divgi, C. R., Yu, M., & Morris, M. J. (2024). A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.267416

Vancouver

Pandit-Taskar N, O'Donoghue JA, Chetty D, Max S, Wanik D, Ilovich O, et al. A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.267416

BibTeX
@article{PanditTaskar2024,
  author = {Pandit-Taskar, Neeta and O'Donoghue, Joseph A and Chetty, Dushen and Max, Steven and Wanik, Danielle and Ilovich, Ohad and Russell, Michael and Nyima, Tenzin and Divgi, Chaitanya R and Yu, Margaret and Morris, Michael J},
  title = {A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.124.267416}
}
Kostenlos starten →